M&A Deal Summary |
|
---|---|
Date | 2005-07-26 |
Target | Ivax |
Sector | Life Science |
Buyer(s) | Teva Pharmaceutical Industries |
Deal Type | Add-on Acquisition |
Deal Value | 7.4B USD |
Advisor(s) | UBS Investment Bank (Financial) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1901 |
Sector | Life Science |
Employees | 35,001 |
Revenue | 15.8B USD (2023) |
Teva Pharmaceutical Industries is a provider of pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Teva Pharmaceutical Industries was founded in 1901 and is based in Tel Aviv, Israel.
DEAL STATS | # |
---|---|
Overall | 5 of 23 |
Sector (Life Science) | 5 of 20 |
Type (Add-on Acquisition) | 4 of 19 |
State (Florida) | 1 of 1 |
Country (United States) | 3 of 15 |
Year (2005) | 1 of 1 |
Size (of disclosed) | 3 of 14 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2004-01-22 |
Sicor
Irvine, California, United States Sicor, Inc. is a vertically integrated specialty pharmaceutical company with expertise in the development, manufacturing and marketing of generic injectable pharmaceutical products. |
Buy | $3.4B |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2008-01-22 |
CoGenesys
Rockville, Maryland, United States CoGenesys, Inc. is a biopharmaceutical company with a broad based biotechnology platform and focused on the development of peptide- and protein-based medicines across broad therapeutic categories. |
Buy | - |